Fetuin-A (AHSG) Human ELISA

Summary

Fetuin-A (AHSG), a 59 kDa glycoprotein, consisting of two cystatin-like domains and a smaller unrelated domain, is predominantly sinthetized in liver . It is secreted into the blood stream and deposited as a noncollagenous protein in mineralized bones and teeth. Fetuin-A occurs in high serum concentrations during foetal life, whereas its level declines following infection, inflamatory and malignancy. Fetuin-A acts as an important circulating inhibitor of ectopic calcification, frequent complication of many degenerative diseases. Low serum level of Fetuin-A is associated with vascular and valvular calcification, atherosclerosis, malnutrition and higher cardiovascular mortality in chronic renal failure, liver cancer and liver cirrhosis patients on long-term dialysis. AHSG protein represents a natural inhibitor of tyrosinase kinase activity of the insulin receptor. It may play a significant role in regulating postprandial glucose disposal, insulin sensitivity, weight gain, and fat accumulation. The serum and bone-resident Fetuin-A binds to transforming growth factor- β and blocks TGF-β binding to cell surface receptors.

Features

• The total assay time is less than 3 hours.
• The kit measures serum or plasma Fetuin-A.
• Calibrator is human plasma based.
• Quality Controls are human serum based.
• Components of the kit are provided ready-to-use, concentrated and lyophilized.

Research topic

Bone and cartilage metabolism, Renal disease

Assay format

Sandwich ELISA, HRP-labelled antibody

Applications

Plasma, Serum

Sample requirements

10 µl/well

Storage/Shipping

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration range

2 – 100 ng/ml

Limit of detection

Analytical Limit of Detection is calculated from the real Fetuin-A values in wells and is 0.35 ng/ml

Intra-assay (Within-Run, n=8)

CV = 3.5 %

Inter-assay (Run-to-Run, n=5)

CV = 5.4 %

Spiking Recovery

102.8 %

Dilution Linearity

95.9 %

Cross-Reactivity

Goat

References to this product

• Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU . Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care . Apr;29(4):853-7 (2006)
• Katayama H, Paczesny S, Prentice R, Aragaki A, Faca VM, Pitteri SJ, Zhang Q, Wang H, Silva M, Kennedy J, Rossouw J, Jackson R, Hsia J, Chlebowski R, Manson J, Hanash S. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med. 2009;1 (4):47
• Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, Lee E, Motoyama K, Koyama H, Shoji T, Inaba M, Nishizawa Y . Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) . Feb;66(2):246-50 (2007)
• Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y . Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care . Feb;29(2):468 (2006)
• Blaha V, Mistrik E, Dusilova-Sulkova S, Kalousova M, Andrys C, Blaha M, Sobotka L. Circulating fetuin-A predicts early mortality in chronic hemodialysis patients. Clin Biochem. 2009 Jul;42 (10-11):996-1000
• Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S. Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index?. Blood Purif. 2010;29 (1):13-22
• Tumani H, Lehmensiek V, Rau D, Guttmann I, Tauscher G, Mogel H, Palm C, Hirt V, Suessmuth SD, Sapunova-Meier I, Ludolph AC, Brettschneider J. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett. 2009 Mar 13;452 (2):214-7
• Ziolkowska H, Brzewski M, Roszkowska-Blaim M. Determinants of the intima-media thickness in children and adolescents with chronic kidney disease. Pediatr Nephrol. 2008 May;23 (5):805-11
• Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008 May;23 (5):1621-7
• Oikawa O, Higuchi T, Yamazaki T, Yamamoto C, Fukuda N, Matsumoto K. Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. Clin Exp Nephrol. 2007 Dec;11 (4):304-8
• Kaushik SV, Plaisance EP, Kim T, Huang EY, Mahurin AJ, Grandjean PW, Mathews ST. Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes Metab Res Rev. 2009 Jul;25 (5):427-34
• Roos M, Richart T, Kouznetsova T, von Eynatten M, Lutz J, Heemann U, Baumann M, Staessen JA. Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept. 2009 Apr 10;154 (1-3):39-43
• Urbanova M, Kalousova M, Zima T, Skibova J, Wohlfahrt P, Viklicky O. Fetuin-A early after renal transplantation. Kidney Blood Press Res. 2009;32 (3):217-22
• Wojtysiak-Duma B, Duma D, Burska A, Janicki K, Zakaszewska K, Skałecki P, Janicka L, Solski J. Fetuin-A in patients undergoing peritoneal dialysis with coronary artery calcification. Annales Universitatis Marie Cu. XXI, N 1, 68, 2008
• Ford ML, Tomlinson LA, Smith ER, Rajkumar C, Holt SG. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant. 2010 Jan 14;
• Eller P, Hochegger K, Feuchtner GM, Zitt E, Tancevski I, Ritsch A, Kronenberg F, Rosenkranz AR, Patsch JR, Mayer G. Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrol Dial Transplant. 2008 Jan;23 (1):321-7
• Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J, Hendrich C, Ludolph AC, Tumani H. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett. 2010 Jan 1;468 (1):23-7
• Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Willé DR, Wu W, Yates JW, Gloger IS. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics. 7 Mar 2008;2 Issue 4:467 - 477
• Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, Tarelli E, Howe FA, Bell BA, Papadopoulos MC. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem. 2008 Apr;54 (4):713-22
• Pertosa G, Simone S, Ciccone M, Porreca S, Zaza G, Dalfino G, Memoli B, Procino A, Bonomini M, Sirolli V, Castellano G, Gesualdo L, Ktena M, Schena FP, Grandaliano G. Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis?. Am J Kidney Dis. 2009 Mar;53 (3):467-74
• Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C. Serum fetuin--a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine. 2008 Dec;44 (3):323-7
• Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B. Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract. 2008;108 (3):c233-40
• Briana DD, Boutsikou M, Gourgiotis D, Boutsikou T, Baka S, Marmarinos A, Hassiakos D, Malamitsi-Puchner A. Serum fetuin-A/alpha2-HS-glycoprotein in human pregnancies with normal and restricted fetal growth. J Matern Fetal Neonatal Med. 2008 Nov;21 (11):826-30
• Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008 Jan;3 (1):61-8
• Kaden JJ, Reinohl JO, Blesch B, Brueckmann M, Haghi D, Borggrefe M, Schmitz F, Klomfass S, Pillich M, Ortlepp JR. Systemic and local levels of fetuin-A in calcific aortic valve stenosis. Int J Mol Med. 2007 Aug;20 (2):193-7
• Uz O, Kardesoglu E, Yiginer O, Bas S, Ipcioglu OM, Ozmen N, Aparci M, Cingozbay BY, Isilak Z, Cebeci BS. The relationship between coronary calcification and the metabolic markers of osteopontin, fetuin-A, and visfatin. Turk Kardiyol Dern Ars. 2009 Sep;37 (6):397-402
• Stejskal D, Karpisek M, Vrtal R, Student V, Solichova P, Fiala R, Stejskal P. Urine fetuin-A values in relation to the presence of urolithiasis. BJU Int. 2008 May;101 (9):1151-4
• Panczyk-Tomaszewska M, Skrzypczyk P, Ziolkowska H, Adamczuk D, Roszkowska-Blaim M. [Fetuin A in children with nephrotic syndrome]. Pol Merkur Lekarski. 2008;24 Suppl 4:65-7
• Ziolkowska H, Wojnar J, Panczyk-Tomaszewska M, Roszkowska-Blaim M. [Fetuin A in children with renal diseases]. Przegl Lek. 2006;63 Suppl 3:54-6

References to summary

• Lebreton J.P., Joisel F., Raoult J.P., Lannuzel B., Rogez J.P., Humbert G.: Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64: 1118–1129
• Schinke T., Amendt C., Trindl A., Poeschke O., Mueller-Esterl W., Jahnen-Dechent W.: The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996; 271: 20789–96
• Osawa M., Umetsu K., Sato M., Ohki T., Yukawa N., Suzuki T., Takeichi S.: Structure of the gene encoding human alpha 2-HS glycoprotein. Gene 1997; 196: 121–125
• Mathews S. T., Chellam N., Srinivas P. R., Cintron V. J., Leon M. A., Goustin A. S., Grungerger G.: Alpha2-HSG, a specific inhibitor of insulin receptor autophosphory­lation, interacts with the insulin receptor. Moll Cell Endocrinol 2000; 164: 87–98
• Heiss A., DuChesne A., Denecke B., Grotzinger J., Yamamoto K., Renne T., Jahnen-Dechent W.: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A: formation of colloidal calciprotein particles. J Biol Chem 2003; 278: 13333–13341
• Ketteler M., Bongartz P., Westenfeld R., Ernst Wildberger J., Horst Mahnken A., Boehm R., Metzger T., Wanner C., Jahnen-Dechent W., Floege J.: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827–833
• Schafer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., Muller-Esterl W., Schinke T., Jahnen-Dechent W.: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357–366
• Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., Davidsson P.: Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's di­sease. Brain Res Mol Brain Res 2003; 118: 140–146
• Kwak J.Y., Ma T.Z., Yoo M.J., Hee Choi B., Kim H.G., Kim S.R., Yim C.Y., Kwak Y.G.: The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol 2004; 32: 836–842
• Floege J., Ketteler M.: Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004; 19 Suppl 5: V59–66. Review
• Wang A.Y., Woo J., Lam C.W., Wang M., Chan I.H., Gao P., Liu S.F., Li P.K., Sanderson J.E.: Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: 1676–1685
• Osawa M., Tian W., Horiuchi H., Kaneko M., Umetsu K.: Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet 2005; 116: 146–151
• Mehrotra R., Westenfeld R., Christenson P., Budoff M., Ipp E., Takasu J., Gupta A., Norris K., Ketteler M., Adler S.: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005; 67: 1070–1077
• Kundranda M.N., Henderson M., carter K.J., Gorden L., Binhazim A., Ray S., Baptiste T., Shokrani M., Leite-Browning M.L., Jahnen-Dechent W., Matrisian L.M. Ochieng J.: The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesiveindependent mechanisms. Cancer Res 2005; 65: 499–506 Human Fetuin-A ELISA (page 24 of 28) VERSION: 33 290807 07
• Geroldi D., Minoretti P., Bianchi M., Di Vito C. Reino M., Bertona M., Emanuele E.: Genetic association of alpha2-Heremans-Schmid glycoprotein polymorphism with late-onset Alzheimer's disease in Italians. Neurosci Lett 2005; 386: 176–178
• Reynolds J.L., Skepper J.N., McNair R., Kasama T., Gupta K., Wissberg P.L., Jahnen-Dechent W., Shanahan C.M.: Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16: 2920–2930
• Ix J.H., Shilipak M.G., Brandenburg V.M., Ali S., Ketteler M., Whooley M.A.: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006; 113: 1760–1767
• Zhou H., Pisitkun T., Aponte A., Yuen P.S., Hoffert J.D., Yasuda H., Hu X., Chawla L., Shen R.F., Knepper M.A., Star R.A.: Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int 2006; 70: 1847–1857

By research topic:

• Bone and cartilage metabolism
• Renal disease

By molecule:

• Fetuin-A

Registration form